✦ LIBER ✦

Efficacy and Safety of Intravenous Solanezumab in Patients with Mild to Moderate Alzheimer's Disease: Results of Two Phase 3 Studies

✍ Scribed by Hake, Ann M.; Siemers, Eric; Carlson, Christopher; Estergard, Wahiba; Sundell, Karen; Henley, David; Eads, Jennifer; Sexton, Cora; Dean, Robert A.; Willis, Brian; DeMattos, Ronald; Mohs, Richard

Book ID: 123535733
Publisher: American Psychiatric Publishing Inc
Year: 2013
Tongue: English
Weight: 50 KB
Volume: 21
Category: Article
ISSN: 1064-7481
DOI: 10.1016/j.jagp.2012.12.182

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of solanezumab in patients with

Efficacy of solanezumab in patients with mild or moderate Alzheimer's disease: Pooled analyses findings from two phase III studies

✍ Carlson, Christopher; Sundell, Karen; Estergard, Wahiba; Raskin, Joel; Liu-Seife 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Effects of solanezumab versus placebo ad

Effects of solanezumab versus placebo administration on biomarkers in people with mild-to-moderate Alzheimer's disease: Results from two phase III clinical trials

✍ Dean, Robert; Siemers, Eric; Carlson, Christopher; Estergard, Wahiba; Sundell, K 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 56 KB

Two Phase 3 Trials of Bapineuzumab in Mi

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

✍ Salloway, Stephen; Sperling, Reisa; Fox, Nick C.; Blennow, Kaj; Klunk, William; 📂 Article 📅 2014 🏛 Massachusetts Medical Society 🌐 English ⚖ 620 KB

Long-term efficacy and safety of galanta

Long-term efficacy and safety of galantamine in patients with mild-to-moderate Alzheimer's disease: multicenter trial

✍ T. Pirttilä; G. Wilcock; L. Truyen; C. V. Damaraju 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 203 KB

Efficacy and safety of tarenflurbil in m

Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial

✍ Gordon K Wilcock; Sandra E Black; Suzanne B Hendrix; Kenton H Zavitz; Edward A S 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 199 KB

Results of the GAP 160701 study: A phase

Results of the GAP 160701 study: A phase 3 clinical trial of intravenous immunoglobulin for mild-to-moderate Alzheimer's disease

✍ Relkin, Norman 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB